A Randomized, Double-Blind, Placebo-Controlled, Multi-centre, Phase III Study of Post-Operative Adjuvant Lapatinib or Placebo and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib or Placebo Monotherapy in High-Risk Subjects with Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Latest Information Update: 08 May 2023
At a glance
- Drugs Lapatinib (Primary) ; Cisplatin
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms MAINTYNANCE
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 01 Apr 2023 Results of secondary analysis finding Association of Surgical Margin Distance With Survival in Patients With Resected Head and Neck Squamous Cell Carcinoma, published in the JAMA Otolaryngology-- Head and Neck Surgery
- 05 Jun 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 02 Nov 2015 Results published in the Journal of Clinical Oncology